Molecular diagnosis of COVID-19 primarily relies on the detection of RNA of the SARS-CoV-2 virus, the causative infectious agent of the pandemic. Reverse transcription polymerase chain reaction (RT-PCR) enables sensitive detection of specific sequences of genes that encode the RNA dependent RNA polymerase (RdRP), nucleocapsid (N), envelope (E), and spike (S) proteins of the virus. Although RT-PCR tests have been widely used and many alternative assays have been developed, the current testing capacity and availability cannot meet the unprecedented global demands for rapid, reliable, and widely accessible molecular diagnosis. Challenges remain throughout the entire analytical process, from the collection and treatment of specimens to the amplification and detection of viral RNA and the validation of clinical sensitivity and specificity. We highlight the main issues surrounding molecular diagnosis of COVID-19, including false negatives from the detection of viral RNA, temporal variations of viral loads, selection and treatment of specimens, and limiting factors in detecting viral proteins. We discuss critical research needs, such as improvements in RT-PCR, development of alternative nucleic acid amplification techniques, incorporating CRISPR technology for point-of-care (POC) applications, validation of POC tests, and sequencing of viral RNA and its mutations. Improved assays are also needed for environmental surveillance or wastewater-based epidemiology, which gauges infection on the community level through analyses of viral components in the community's wastewater. Public health surveillance benefits from large-scale analyses of antibodies in serum, although the current serological tests do not quantify neutralizing antibodies. Further advances in analytical technology and research through multidisciplinary collaboration will contribute to the development of mitigation strategies, therapeutics, and vaccines. Lessons learned from molecular diagnosis of COVID-19 are valuable for better preparedness in response to other infectious diseases.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) protein systems revolutionize genome engineering and advance analytical chemistry and diagnostic technology.
We describe here a binding-facilitated reaction strategy, enabling quantitative conjugation of DNA to native proteins with a desirable 1 : 1 stoichiometry. The technique takes advantage of the iterative affinity interaction and covalent binding processes to achieve complete conjugation. The complete conjugation obviates the need for separation of the protein-DNA conjugates as required by other DNA-protein conjugation methods.
Samples of nasopharyngeal swabs (NPS) are commonly used for the detection of SARS-CoV-2
and diagnosis of COVID-19. As an alternative, self-collection of saliva and gargle
samples minimizes transmission to healthcare workers and relieves the pressure of
resources and healthcare personnel during the pandemic. This study aimed to develop an
enhanced method enabling simultaneous viral inactivation and RNA preservation during
on-site self-collection of saliva and gargle samples. Our method involves the addition
of saliva or gargle samples to a newly formulated viral inactivation and RNA
preservation (VIP) buffer, concentration of the viral RNA on magnetic beads, and
detection of SARS-CoV-2 using reverse transcription quantitative polymerase chain
reaction directly from the magnetic beads. This method has a limit of detection of 25
RNA copies per 200 μL of gargle or saliva sample and 9–111 times higher
sensitivity than the viral RNA preparation kit recommended by the United States Centers
for Disease Control and Prevention. The integrated method was successfully used to
analyze more than 200 gargle and saliva samples, including the detection of SARS-CoV-2
in 123 gargle and saliva samples collected daily from two NPS-confirmed positive
SARS-CoV-2 patients throughout the course of their infection and recovery. The VIP
buffer is stable at room temperature for at least 6 months. SARS-CoV-2 RNA (65
copies/200 μL sample) is stable in the VIP buffer at room temperature for at least
3 weeks. The on-site inactivation of SARS-CoV-2 and preservation of the viral RNA
enables self-collection of samples, reduces risks associated with SARS-CoV-2
transmission, and maintains the stability of the target analyte.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.